We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Jose Miguel Lizcano De Vega, Head of group Protein kinases in cancer research (VHIR)
Summary: I will present the preclinical and clinical development of ABTL0812 (2-hydroxylinoleic acid), a first-in-class anticancer molecule. ABTL0812 selectively kills cancer cells by inducing endoplasmic reticulum (ER) stress and the UPR-mediated cytotoxic autophagy, without affecting healthy cells. Mechanistically, ABTL0812 inhibits desaturase-1, the last enzyme in the ceramide biosynthesis pathway, leading to an accumulation of long-chain dihydroceramides. This, in turn, results in the activation of ER stress and the unfolded protein response (UPR), ultimately inducing cytotoxic autophagy in cancer cells. This represents a novel therapeutic approach, highlighting the potential of ER stressors as effective anticancer agents. Clinical trial data demonstrate that ABTL0812 has a favourable safety and tolerability profile. Phase 2 clinical trials have shown that ABTL0812 enhances the efficacy of standard chemotherapy regimens in patients with advanced squamous non-small cell lung cancer (NSCLC) and advanced endometrial cancer. ABTL0812 is currently in Phase 2b clinical trial, as a first-line therapy in combination with FOLFIRINOX, for patients with advanced or metastatic pancreatic cancer. Additionally, I will present supporting preclinical data that provide a rationale for this clinical trial.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.